STIP1 and Parkinson disease: To further narrow down the binding sites of the autoantibodies, we screened the plasma samples of the 10 Parkinson’s disease patients and five HCs previously defined by the COPA to have high levels of STIP1 autoantibodies (see Figure 2), with the individual peptides from pool 1 and pools 8–10 (Figure 3B).